Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03186326
Title Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer (SAMCO)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Federation Francophone de Cancerologie Digestive
Indications

colorectal adenocarcinoma

Therapies

Aflibercept + Fluorouracil + Irinotecan + Leucovorin

Aflibercept + Fluorouracil + Leucovorin + Oxaliplatin

Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab

Cetuximab + Fluorouracil + Irinotecan + Leucovorin

Bevacizumab + Fluorouracil + Irinotecan + Leucovorin

Fluorouracil + Irinotecan + Leucovorin + Panitumumab

Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin

Avelumab

Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin

Age Groups: senior | adult
Covered Countries

Additional content available in CKB BOOST